Saving orphans: BRAF targeting of histiocytosis

Abstract

In this issue of Blood,Haroche and colleagues report significant therapeutic activity of the BRAF inhibitor, vemurafenib, in 3 patients with rare histiocytic conditions, Erdheim-Chester disease and Langerhans cell histiocytosis. Copyright 2011 by The American Society of Hematology.